Business
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
Announced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGem™ Compared to Systemic
About this update from Renovorx, Inc.
[{"type":"text","content":"\nAnnounced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGem™ Compared to Systemic Chemotherapy in Pancreatic Cancer\n\n\n LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.\n\n\n“We are off to a strong start in 2023, as we build upon the recent positive interim data analysis announced at the American Association of Cancer Research (AACR) Annual Meeting from our open-label Phase III TIGeR-PaC clinical trial with RenovoGem,” said Shaun Bagai, CEO, RenovoRx. “Results of the analysis highlight a trend in median overall survival by 24-weeks and reduced side effects for patients with locally advanced pancreatic cancer (LAPC) with RenovoGem versus systemic chemotherapy. We’re also thrilled to welcome industry veteran Robert J. Spiegel to our Board of Directors, and, clinical trials expert, Leesa Gentry, as our new Senior Vice President of Clinical Operations. We are well positioned to build on our success and momentum, and plan to advance our pipeline of innovative therapies to address unmet medical needs for patients with solid tumor cancers.”\n\n\nOperational Highlights for the First Quarter Ended March 31, 2023:\n\n\n\nAnnounced positive new data from Phase III clinical trial interim analysis. Data suggests a 60% survival benefit and greater than 65% reduction in side effects compared to systemic chemotherapy.\n\n\n\nAnnounced initial results in pharmacokinetic (PK) substudy: data on RenovoGem supports potential for the RenovoTAMP® therapy platform to increase local gemcitabine (chemotherapy) delivery and decrease side effects of pancreatic cancer treatment.\n\n\n\nIssued 8th U.S. patent extending the intellectual property coverage of the RenovoTAMP therapy platform.\n\n\n\nAcceptance of four clinical data abstracts at the 2023 ASCO Gastrointestinal Cancer Symposium.\n\n\n\nHighlights Subsequent to the First Quarter Ended March 31, 2023:\n\n\n\nAppointed Robert J. Spiegel, MD, FACP, former Chief Medical Officer of Schering-Plough, to the Board of Directors.\n\n\n\nAppointed Leesa Gentry as Senior Vice President of Clinical Operations.\n\n\n\nPresented Phase II...